NEW YORK (GenomeWeb News) - An investment banks today upgraded Invitrogen’s stock despite missed second-quarter estimates and revised forecasts.
 
An analyst at Banc of America Securities upgraded the shares to “Buy” from “Neutral” and said the company “will begin to benefit” from the two-year investment in research and development and facility expansions.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.